EA201600497A1 - Оптимизированная фармацевтическая композиция для лечения воспалительных изменений пищевода - Google Patents

Оптимизированная фармацевтическая композиция для лечения воспалительных изменений пищевода

Info

Publication number
EA201600497A1
EA201600497A1 EA201600497A EA201600497A EA201600497A1 EA 201600497 A1 EA201600497 A1 EA 201600497A1 EA 201600497 A EA201600497 A EA 201600497A EA 201600497 A EA201600497 A EA 201600497A EA 201600497 A1 EA201600497 A1 EA 201600497A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
treatment
inflammatory changes
esophagus
optimized pharmaceutical
Prior art date
Application number
EA201600497A
Other languages
English (en)
Other versions
EA029166B1 (ru
Inventor
Роланд Грайнвальд
Ральф Мюллер
Маркус Прёльс
Рудольф Вильхельм
Original Assignee
Др. Фальк Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49911300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201600497(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Др. Фальк Фарма Гмбх filed Critical Др. Фальк Фарма Гмбх
Publication of EA201600497A1 publication Critical patent/EA201600497A1/ru
Publication of EA029166B1 publication Critical patent/EA029166B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описана оптимизированная фармацевтическая композиция для лечения воспалительных изменений пищевода. Такая фармацевтическая композиция ородиспергируемой шипучей таблетки стабильна, проста в приготовлении и применима без необходимости своего растворения в жидкости. Дополнительное запивание, которое сократило бы время нахождения раствора будесонида в соответствующих пораженных отделах пищевода, не требуется. Применение предлагаемой в изобретении шипучей таблетки приводило к неожиданно высокой гистологической ремиссии у пациентов с активным эозинофильным эзофагитом.
EA201600497A 2013-12-23 2014-12-18 Оптимизированная фармацевтическая композиция для лечения воспалительных изменений пищевода EA029166B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199278.6A EP2886108B2 (de) 2013-12-23 2013-12-23 Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus
PCT/EP2014/078391 WO2015097053A1 (de) 2013-12-23 2014-12-18 Optimierte pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des ösophagus

Publications (2)

Publication Number Publication Date
EA201600497A1 true EA201600497A1 (ru) 2017-03-31
EA029166B1 EA029166B1 (ru) 2018-02-28

Family

ID=49911300

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600497A EA029166B1 (ru) 2013-12-23 2014-12-18 Оптимизированная фармацевтическая композиция для лечения воспалительных изменений пищевода

Country Status (24)

Country Link
US (4) US9867780B2 (ru)
EP (2) EP2886108B2 (ru)
JP (3) JP6522626B2 (ru)
CN (1) CN105848648B (ru)
AU (1) AU2014372739B2 (ru)
CA (1) CA2934009C (ru)
CY (2) CY1121168T1 (ru)
DK (2) DK2886108T4 (ru)
EA (1) EA029166B1 (ru)
ES (2) ES2716990T5 (ru)
FI (1) FI2886108T4 (ru)
HK (1) HK1209362A1 (ru)
HR (2) HRP20190677T4 (ru)
HU (2) HUE042009T2 (ru)
IL (1) IL246172B (ru)
LT (2) LT2886108T (ru)
PL (2) PL2886108T5 (ru)
PT (2) PT2886108T (ru)
RS (2) RS58543B2 (ru)
SI (2) SI2886108T2 (ru)
TR (1) TR201815823T4 (ru)
UA (1) UA117162C2 (ru)
WO (1) WO2015097053A1 (ru)
ZA (1) ZA201604225B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704847WA (en) 2009-10-01 2017-07-28 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
HRP20190677T4 (hr) 2013-12-23 2023-02-03 Dr. Falk Pharma Gmbh Optimizirana farmaceutska formula za liječenje upalnih promjena u jednjaku
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP4091615A1 (en) 2021-05-20 2022-11-23 Dr. Falk Pharma Gmbh Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis
CN116869927B (zh) * 2023-09-06 2023-11-10 中国医学科学院北京协和医院 一种用于治疗嗜酸性食管炎的食道温敏凝胶

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3937455A1 (de) * 1989-11-10 1991-05-16 Nordmark Arzneimittel Gmbh Antacidatabletten
DK0481294T4 (da) * 1990-10-19 2001-06-18 Spirig Ag Fast, hurtigt-opløseligt lægemiddelpræparat indeholdende N-acetylcystein
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2834893B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de perindopril
US20030215502A1 (en) 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
EP1595533B1 (en) 2003-01-21 2010-01-06 Nippon Shinyaku Co., Ltd. Tablet quickly melting in oral cavity
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060013873A1 (en) 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20070071817A1 (en) 2005-09-26 2007-03-29 Phyzz, Inc. Effervescent oral care compositions and method of use
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009526860A (ja) 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 安定したコルチコステロイド混合物
EP2572705B1 (en) 2007-10-01 2017-09-13 Laboratorios Lesvi, S.L. Orodispersible tablets
SI3354276T1 (sl) 2007-11-13 2020-09-30 Meritage Pharma, Inc. Sestavki za zdravljenje gastrointestinalnega vnetja
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
ES2358158T3 (es) * 2008-07-21 2011-05-06 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento del tracto digestivo superior.
CN102112114A (zh) 2008-08-08 2011-06-29 麦克内尔-Ppc股份有限公司 使用三氯蔗糖作为制粒剂
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
HRP20190677T4 (hr) 2013-12-23 2023-02-03 Dr. Falk Pharma Gmbh Optimizirana farmaceutska formula za liječenje upalnih promjena u jednjaku

Also Published As

Publication number Publication date
JP2020196753A (ja) 2020-12-10
US10369100B2 (en) 2019-08-06
ES2716990T3 (es) 2019-06-18
HUE041911T2 (hu) 2019-06-28
SI3086782T1 (sl) 2018-11-30
DK3086782T3 (en) 2018-11-26
HRP20181799T1 (hr) 2018-12-28
EA029166B1 (ru) 2018-02-28
US9867780B2 (en) 2018-01-16
RS58543B1 (sr) 2019-04-30
SI2886108T1 (sl) 2019-05-31
NZ721495A (en) 2020-12-18
US11382860B2 (en) 2022-07-12
JP2017500361A (ja) 2017-01-05
ES2694331T3 (es) 2018-12-19
DK2886108T3 (en) 2019-04-01
RS58112B1 (sr) 2019-02-28
US20180185277A1 (en) 2018-07-05
FI2886108T4 (fi) 2023-02-22
ES2716990T5 (es) 2023-03-24
CA2934009A1 (en) 2015-07-02
EP2886108B2 (de) 2022-11-02
SI2886108T2 (sl) 2023-02-28
CY1121168T1 (el) 2020-05-29
EP3086782B1 (de) 2018-09-26
PT3086782T (pt) 2018-11-19
RS58543B2 (sr) 2023-02-28
CN105848648A (zh) 2016-08-10
TR201815823T4 (tr) 2018-11-21
CY1121523T1 (el) 2020-05-29
HRP20190677T1 (hr) 2019-05-31
HK1209362A1 (en) 2016-04-01
JP7009575B2 (ja) 2022-01-25
JP6522626B2 (ja) 2019-05-29
LT3086782T (lt) 2018-11-26
DK2886108T4 (da) 2023-01-30
PT2886108T (pt) 2019-04-01
JP6757444B2 (ja) 2020-09-16
CN105848648B (zh) 2019-08-06
PL3086782T3 (pl) 2019-03-29
WO2015097053A1 (de) 2015-07-02
PL2886108T3 (pl) 2019-08-30
EP2886108B1 (de) 2019-02-06
AU2014372739A1 (en) 2016-07-07
PL2886108T5 (pl) 2023-02-27
UA117162C2 (uk) 2018-06-25
EP3086782A1 (de) 2016-11-02
US20190358155A1 (en) 2019-11-28
US20160324772A1 (en) 2016-11-10
AU2014372739B2 (en) 2019-06-13
US20200337997A1 (en) 2020-10-29
IL246172B (en) 2019-01-31
CA2934009C (en) 2020-03-10
LT2886108T (lt) 2019-03-25
HUE042009T2 (hu) 2019-06-28
IL246172A0 (en) 2016-07-31
EP2886108A1 (de) 2015-06-24
US10695291B2 (en) 2020-06-30
ZA201604225B (en) 2017-08-30
HRP20190677T4 (hr) 2023-02-03
JP2019142931A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
EA201600497A1 (ru) Оптимизированная фармацевтическая композиция для лечения воспалительных изменений пищевода
IN2015DN00544A (ru)
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
GT201400285A (es) Formulacion de anticuerpos
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201991484A1 (ru) Лекарственные формы энзалутамида
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
AR105712A1 (es) Composiciones de insulina de rápida acción
BR112015027477A8 (pt) bolus, seus usos, e kit
EA201592227A1 (ru) Стабильные растворы объединенных активных фармацевтических ингредиентов для перорального применения
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
CL2016002510A1 (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano [3,4-d][1,3] tiazin-8a(8h)-il-1,3-tiazol-4-ilamidas.
MX2016005395A (es) Formulacion estable de insulina glulisina.
IL240949B (en) Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes
EA201591698A1 (ru) Макроциклические ингибиторы киназы lrrk2
EA201692392A1 (ru) Новая лекарственная форма мелоксикама
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
MD20180049A2 (ru) Фармацевтическая композиция
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
TR201908937T4 (tr) P38 MAP kinazı inhibe eden indanil üre bileşikleri.
EA201690762A1 (ru) {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM